ACHN Achillion Pharmaceuticals Inc.

3.11
+0.04  (+1%)
Previous Close 3.07
Open 3.16
Price To Book 1.54
Market Cap 431096289
Shares 138,616,170
Volume 2,038,362
Short Ratio
Av. Daily Volume 1,628,722

SEC filingsSee all SEC filings

  1. 8-K - Current report 181216847
  2. 8-K - Current report 181198274
  3. 8-K - Current report 181166314
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166231
  5. 8-K - Current report 181061419

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due December 17, 2018.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 interim data due December 17, 2018.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
Phase 2 updated data due December 17, 2018.
ACH-4471
C3 glomerulopathy (C3G)
Phase 1 interim data due December 17, 2018.
ACH-5228
Healthy volunteers
Phase 1 interim data due December 17, 2018.
ACH-5548
Healthy volunteers

SEC Filings

  1. 8-K - Current report 181216847
  2. 8-K - Current report 181198274
  3. 8-K - Current report 181166314
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166231
  5. 8-K - Current report 181061419
  6. S-8 - Securities to be offered to employees in employee benefit plans 181002023
  7. 8-K - Current report 181001543
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001478
  9. 8-K - Current report 18875108
  10. DEFR14A - Revised definitive proxy soliciting materials 18804588